BACKGROUND: Endotoxin-induced uveitis (EIU) is a model for acute anterior uveitis associated with a variety of pro-inflammatory cytokines and nitric oxide production. Interleukin 10 (IL-10) down-regulates these inflammatory mediators. We report a study of the effect of systemic administration of IL-10 on the inflammatory parameters of EIU. METHODS: Uveitis was induced in C3H/HeN mice by subcutaneous injection of 200 micrograms lipopolysaccharide (LPS) per mouse. Intraocular inflammation was assessed by leukocyte count and measurement of the protein concentration in the aqueous humor (AH). Mouse recombinant IL-10 at 1000 U or its vehicle alone were administered by three intravenous injections given 4.0 h and 0.5 h before and 8.0 h after LPS injection. RESULTS: The inflammatory cell infiltration in the eyes was significantly reduced in four of five experiments from 40% to 64% in the groups treated with IL-10 compared to the control groups (P < 0.05). In contrast, the level of protein exudation in the anterior chamber (AC) was not significantly affected by IL-10 treatment. CONCLUSION: IL-10 reduces the cellular infiltration in the ocular inflammation produced by endotoxin. This result suggests potential usefulness for IL-10 in the treatment of severe anterior uveitis with a strong cellular component.
BACKGROUND: Endotoxin-induced uveitis (EIU) is a model for acute anterior uveitis associated with a variety of pro-inflammatory cytokines and nitric oxide production. Interleukin 10 (IL-10) down-regulates these inflammatory mediators. We report a study of the effect of systemic administration of IL-10 on the inflammatory parameters of EIU. METHODS:Uveitis was induced in C3H/HeN mice by subcutaneous injection of 200 micrograms lipopolysaccharide (LPS) per mouse. Intraocular inflammation was assessed by leukocyte count and measurement of the protein concentration in the aqueous humor (AH). Mouse recombinant IL-10 at 1000 U or its vehicle alone were administered by three intravenous injections given 4.0 h and 0.5 h before and 8.0 h after LPS injection. RESULTS: The inflammatory cell infiltration in the eyes was significantly reduced in four of five experiments from 40% to 64% in the groups treated with IL-10 compared to the control groups (P < 0.05). In contrast, the level of protein exudation in the anterior chamber (AC) was not significantly affected by IL-10 treatment. CONCLUSION:IL-10 reduces the cellular infiltration in the ocular inflammation produced by endotoxin. This result suggests potential usefulness for IL-10 in the treatment of severe anterior uveitis with a strong cellular component.
Authors: A Delvaux; V Donckier; C Bruyns; S Florquin; C Gérard; Z Amraoui; D Abramowicz; M Goldman; T Velu Journal: Transplantation Date: 1994-10-27 Impact factor: 4.939
Authors: A Marchant; C Bruyns; P Vandenabeele; M Ducarme; C Gérard; A Delvaux; D De Groote; D Abramowicz; T Velu; M Goldman Journal: Eur J Immunol Date: 1994-05 Impact factor: 5.532
Authors: R G Tilton; K Chang; J A Corbett; T P Misko; M G Currie; N S Bora; H J Kaplan; J R Williamson Journal: Invest Ophthalmol Vis Sci Date: 1994-07 Impact factor: 4.799
Authors: C Gérard; C Bruyns; A Marchant; D Abramowicz; P Vandenabeele; A Delvaux; W Fiers; M Goldman; T Velu Journal: J Exp Med Date: 1993-02-01 Impact factor: 14.307
Authors: P Durez; D Abramowicz; C Gérard; M Van Mechelen; Z Amraoui; C Dubois; O Leo; T Velu; M Goldman Journal: J Exp Med Date: 1993-02-01 Impact factor: 14.307
Authors: Zhuqing Li; Baoying Liu; Arvydas Maminishkis; Sankaranarayana P Mahesh; Steven Yeh; Julie Lew; Wee Kiak Lim; H Nida Sen; Grace Clarke; Ronald Buggage; Sheldon S Miller; Robert B Nussenblatt Journal: J Immunol Date: 2008-10-01 Impact factor: 5.422
Authors: Cristhian J Ildefonso; Henrique Jaime; Manas R Biswal; Shannon E Boye; Qiuhong Li; William W Hauswirth; Alfred S Lewin Journal: Mol Ther Date: 2015-02-20 Impact factor: 11.454
Authors: P Trittibach; S E Barker; C A Broderick; M Natkunarajah; Y Duran; S J Robbie; J W B Bainbridge; A J Smith; G-M Sarra; A D Dick; R R Ali Journal: Gene Ther Date: 2008-06-26 Impact factor: 5.250
Authors: Y De Kozak; B Thillaye-Goldenberg; M-C Naud; A Vianna Da Costa; C Auriault; C Verwaerde Journal: Clin Exp Immunol Date: 2002-11 Impact factor: 4.330
Authors: Md Huzzatul Mursalin; Phillip S Coburn; Frederick C Miller; Erin T Livingston; Roger Astley; Michelle C Callegan Journal: Invest Ophthalmol Vis Sci Date: 2020-11-02 Impact factor: 4.799
Authors: Philip C Robinson; Theodora A M Claushuis; Adrian Cortes; Tammy M Martin; David M Evans; Paul Leo; Pamela Mukhopadhyay; Linda A Bradbury; Katie Cremin; Jessica Harris; Walter P Maksymowych; Robert D Inman; Proton Rahman; Nigil Haroon; Lianne Gensler; Joseph E Powell; Irene E van der Horst-Bruinsma; Alex W Hewitt; Jamie E Craig; Lyndell L Lim; Denis Wakefield; Peter McCluskey; Valentina Voigt; Peter Fleming; Mariapia Degli-Esposti; Jennifer J Pointon; Michael H Weisman; B Paul Wordsworth; John D Reveille; James T Rosenbaum; Matthew A Brown Journal: Arthritis Rheumatol Date: 2015-01 Impact factor: 10.995